Clear Labs, a leader in automated genomic sequencing solutions, is proud to announce the release of its latest product, Clear Dx™ Deeplex® Myc-TB, an automated version of the widely used Deeplex® Myc-TB assay from GenoScreen. This cutting-edge product is optimized for use with the Clear Dx™ platform and is now available for Research Use Only (RUO).
Mycobacterium tuberculosis (TB) remains one of the world’s deadliest infectious diseases, with an estimated 10 million new cases and 1.5 million deaths annually, according to the World Health Organization. Additionally, non-tuberculous mycobacteria (NTM) are an emerging public health concern, increasingly associated with pulmonary and other infections. TB drug resistance is also on the rise, complicating treatment and prolonging recovery. These challenges make accurate, rapid, and comprehensive detection of TB and NTM critical for effective research and potential clinical intervention.
Traditional methods for detecting TB and NTM, such as culture-based techniques, smear microscopy, and drug susceptibility testing, are often time-consuming, requiring several weeks for results. They also face limitations in sensitivity and specificity, which can delay treatment and hinder efforts to control the spread of resistant strains. Additionally, manual workflows are prone to human error, requiring significant expertise and leading to higher operational costs. These pitfalls create barriers to rapid and accurate detection, which is especially critical in the face of rising drug resistance.
The Clear Dx™ Deeplex® Myc-TB offers a comprehensive solution for the species identification and characterization of TB and NTM, directly from DNA extracted from clinical specimens. In addition to microbial identification, the product enables the detection of mutations associated with TB drug resistance, offering critical insights for research into resistant strains.
Also Read: Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
“We are thrilled to partner with Clear Labs in bringing the Clear Dx™ Deeplex® Myc-TB to market,” said André Tordeux, CEO of GenoScreen. “This collaboration merges our advanced TB detection technology with Clear Labs’ automated platform, providing the healthcare and scientific community with a seamless, efficient solution for mycobacterial species identification and drug resistance mutation detection. Together, we’re advancing TB research and offering labs the tools they need to better understand and tackle this critical global health challenge.”
“We are excited to bring Clear Dx™ Deeplex® Myc-TB to market, offering an efficient, automated solution built on an established, well-regarded assay, with the goal of accelerating the fight against TB,” said Sasan Amini, CEO at Clear Labs. “This product not only enhances lab operations by improving efficiency and accuracy but also addresses key gaps in rapid Mycobacterium characterization. We’re confident it will be a valuable tool for the clinical and scientific community.”
SOURCE: PRWeb